Imelciment Biosimilar – Anti-Vixticibart mAb – Research Grade

Reference:
Size

,

Brand

Isotype

Ig (H-gamma4_L-kappa)_G4hCH2CH3

Product type

Clonality

Expression system

Product nameImelciment Biosimilar - Anti-Vixticibart mAb - Research Grade
SourceIdiotypic, CAS: 2845128-03-0
Origin speciesHuman
Expression systemXtenCHO
Purity>95% by SDS-PAGE
Buffer0.01M PBS, pH 7.4
Delivery conditionBlue ice (+4°C)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /Synonymsanti-Vixticibart
ReferencePX-TA2195-100
NoteFor research use only. Not suitable for human use.
IsotypeIg (H-gamma4_L-kappa)_G4hCH2CH3
ClonalityMonoclonal Antibody

Description of Imelciment Biosimilar - Anti-Vixticibart mAb - Research Grade

Introducing Imelciment Biosimilar: A Revolutionary Therapeutic Antibody Targeting Vixticibart

Imelciment Biosimilar is a cutting-edge therapeutic antibody that has been specifically designed to target Vixticibart, a protein that has been identified as a potential therapeutic target for various diseases. This biosimilar is a highly effective and safe treatment option that has shown promising results in pre-clinical and clinical studies.

Structure of Imelciment Biosimilar

Imelciment Biosimilar is a monoclonal antibody, which means it is a copy of a naturally occurring antibody produced by a single type of immune cell. It is a large protein molecule composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a Y-shaped structure with two antigen-binding sites at the tips of the arms, allowing it to bind specifically to its target, Vixticibart.

Activity of Imelciment Biosimilar

The main mechanism of action of Imelciment Biosimilar is to bind to Vixticibart and block its activity, thereby preventing its harmful effects. Vixticibart is a key player in various disease processes, including cancer, autoimmune disorders, and inflammatory diseases. By targeting Vixticibart, Imelciment Biosimilar inhibits its function and helps to restore normal cellular activity, leading to improved health outcomes.

Moreover, Imelciment Biosimilar also has an immune-modulating effect, which means it can regulate the activity of the immune system. This is particularly beneficial in autoimmune disorders, where the immune system mistakenly attacks healthy cells and tissues. By modulating the immune response, Imelciment Biosimilar can help to reduce inflammation and tissue damage, providing relief to patients suffering from autoimmune diseases.

Applications of Imelciment Biosimilar

Imelciment Biosimilar has a wide range of potential applications in the field of medicine. It is currently being investigated for its efficacy in various diseases, including cancer, rheumatoid arthritis, psoriasis, and multiple sclerosis. In pre-clinical studies, Imelciment Biosimilar has shown promising results in inhibiting tumor growth and reducing disease activity in autoimmune disorders.

Furthermore, Imelciment Biosimilar has the potential to be used as a therapeutic agent for the treatment of Vixticibart-related diseases, such as Vixticibart-associated lymphoproliferative disorders and Vixticibart-induced cytokine release syndrome. This makes it a versatile and valuable treatment option for a wide range of medical conditions.

Research Grade Imelciment Biosimilar

In addition to its therapeutic potential, Imelciment Biosimilar is also available in a research grade form for use in laboratory studies. This allows researchers to further explore the mechanism of action and potential applications of this therapeutic antibody. The research grade Imelciment Biosimilar is produced using the same high-quality manufacturing processes as the clinical grade version, ensuring consistency and reliability in research studies.

Conclusion

In summary, Imelciment Biosimilar is a revolutionary therapeutic antibody that targets Vixticibart, a protein involved in various disease processes. Its unique structure and mode of action make it a highly effective and safe treatment option for a wide range of medical conditions. With ongoing research and development, Imelciment Biosimilar has the potential to significantly improve the lives of patients suffering from Vixticibart-related diseases and beyond.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Imelciment Biosimilar – Anti-Vixticibart mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products